Filing Flows › Tarsus Pharmaceuticals (TARS) › Q2 2026
Tarsus Pharmaceuticals (TARS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Tarsus Pharmaceuticals (TARS) reported revenue of $174M for the second quarter 2026 (Q2 2026), +69% from a year earlier and +7% from the quarter before. Operating margin was -11.4%, net loss $18.6M (10.7% of revenue).
Tarsus Pharmaceuticals, Q2 2026: revenue $174M (+69% year over year), operating margin -11.4%, net loss $18.6M, operating cash flow $61.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $174M | +7% | +69% |
| Operating profit | −$19.9M | — | — |
| Net earnings | −$18.6M | — | — |
| Operating cash flow | $61.2M | — | — |
| Free cash flow | $57.2M | — | — |
What changed
Revenue was $173.9M in Q2 2026, up 69% year over year and up 7% from the previous quarter.
Operating costs exceeded revenue by $19.9M, an operating margin of -11.4%. Total costs grew 55% against revenue growth of 69%. The fastest-growing cost line was Research & development (+99%). The quarter ended with a net loss of $18.6M, wider than the previous quarter's $7.0M loss. Non-operating items added $4.1M, -26% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $61.2M. Non-cash charges added back $1.0M of depreciation and amortization and $13.3M of share-based compensation. Working capital and other items added $65.5M. Capital expenditures of $4.1M left free cash flow of $57.2M.
Questions
What was Tarsus Pharmaceuticals' revenue in the second quarter 2026?
Tarsus Pharmaceuticals (TARS) reported revenue of $174M for the second quarter 2026 (Q2 2026), +69% from a year earlier and +7% from the quarter before.
Was Tarsus Pharmaceuticals profitable in the second quarter 2026?
Operating loss was $19.9M (-11.4% of revenue) and net loss $18.6M.